Neurocognitive disorders include dementia, delirium, and mild cognitive impairment, which is characterized by decline of the level of cognitive functioning. Neurocognitive deficit is a reduction or impairment of cognitive functions and affects nerve cells and often impact the person’s ability to remember, to reason, and to make judgments. The neurocognitive disorders have different clinical characteristics with Alzheimer disease, front temporal degeneration, cerebrovascular disease, traumatic brain injury, Lewy body disease, and infections showing the common causes. Alzheimer disease is the most common cause of neurocognitive disorder. In the early stages of Alzheimer, people are not able to remember the recent events, conversations, and names of people and may also experience the depression. Individuals with neurocognitive disorder show the side effects like mood disturbances including apathy, depression, anxiety and sleep disturbance including insomnia, hypersomnia.

Neurocognitive disorder treatments include pain medications, surgeries, physical therapy, bed rest, and others. Furthermore, for treatment of neurocognitive disorder, antibiotics are used to clear the remaining infections, which is affecting the brain, such as meningitis.

Global Neurocognitive Disorder Treatment Market: Market Dynamics

Increasing prevalence of neurocognitive disorder is expected to augment the global neurocognitive disorder treatment market growth. Due to advancement in technology and inventions such as Al and adoption of unhealthy work practices, increased cardiovascular issues are boosting the global neurocognitive disorder market. Moreover, increased addiction of drugs and alcohol in youth and also changing climate conditions or respiratory diseases are causing neurocognitive disorders and driving the market growth. Furthermore, increase in number of geriatric population is also the factor affecting the market growth. Approvals of the drugs associated with the treatment from the regulatory bodies is the factor that drives the market growth. For instance, on April 11, 2019, the U.S.FDA accepted the resubmitted new drug application (NDA) for instradefylline (KW-6002), which is an oral selective adenosine receptor antagonist for use as adjunctive treatment for Parkinson’s disease in adults. On May 20, 2019, the U.S.FDA approved Neuronascent Investigational New Drug (IND) application for NNI-362.

The clinical trials of some drugs are terminated, as they are not able to reach to their primary endpoint. For instance, on March 21, 2019, Biogen and Eisei, Co., Ltd announced the decision to discontinue the global phase 3 trial of Aducanumab, which is designed to evaluate the safety and efficacy of an antibody-aducanumab in patients with Alzheimer disease. This decision to stop the trial is based on the analysis that trials were unlikely to improve the people’s memory and thinking sufficiently by the end of the trial. This discontinuation of trials is the major restraining factor for the market.

Global Neurocognitive Disorder Treatment Market: Regional Dynamics

North America is expected to hold a dominant position in the global neurocognitive disorder treatment market, owing to adoption of advanced technology and rising number of neurocognitive disorder patients. According to the World Health Organization (WHO), nearly 35.6 million people live with dementia worldwide. The number of geriatric population worldwide and related dementia patients is expected to rise up to 65.7 million in 2030 and 115.4million in 2050. Furthermore, according WHO, the prevalence of dementia is increasing exponentially with age and sex in North America region, doubling in every 5.5 years. Moreover, satisfactory reimbursement policies, rising adoption of advance precautious methods and increasing penetration of life science analytics for monitoring health changes continuously are factors driving the growth of market in North America.

Global Neurocognitive Disorder Treatment Market: Competitive Landscape

The key players in global neurocognitive disorder treatment market are focusing on developing innovative, new, and efficient neurocognitive disorder treatment drugs that are launched in the market to meet the demand from consumers for various types of neurocognitive disorder treatments. For instance, in March 2018, Biogen announced to enter into an agreement to acquire Pfizer Inc. phase 2b ready AMPA receptor potentiator for cognitive impairment.

Furthermore, in May 2019, T3D therapeutics received grant of US$ 9 million from National Institute on Aging (NIA) to develop drug T3D-959 for neurocognitive disease.

Key players operating in the global neurocognitive disorder treatment market include A B Science, Abbive, A C immune, Biogen, Eisai, Immunobrain, Mediti Pharma Inc., Ono Pharmaceuticals, Proclar Biosciences, Problodrug AG, Roche, T3D Therapeutics, and Purdue Pharma.

Neurocognitive Disorder Treatment Market: Market Taxonomy

On the basis of disorder type, the global neurocognitive disorder treatment market is segmented into: